What is Leerink Partnrs’ Forecast for TNYA FY2025 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Stock analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for shares of Tenaya Therapeutics in a report issued on Tuesday, April 1st. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.55) per share for the year, up from their previous forecast of ($0.67). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q4 2025 earnings at ($0.06) EPS.

Several other research analysts have also recently issued reports on TNYA. Chardan Capital reduced their target price on shares of Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 12th. Canaccord Genuity Group reduced their price objective on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. Morgan Stanley lowered their target price on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Tenaya Therapeutics in a research report on Monday. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tenaya Therapeutics presently has an average rating of “Buy” and an average price target of $6.25.

Tenaya Therapeutics Trading Up 4.0 %

TNYA opened at $0.57 on Thursday. The firm has a 50 day moving average of $0.86 and a two-hundred day moving average of $1.65. The firm has a market capitalization of $49.56 million, a PE ratio of -0.39 and a beta of 2.83. Tenaya Therapeutics has a 12-month low of $0.39 and a 12-month high of $5.10.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Insider Buying and Selling at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III acquired 35,714,284 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were acquired at an average cost of $0.70 per share, with a total value of $24,999,998.80. Following the completion of the acquisition, the insider now directly owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This trade represents a 262.62 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have sold 19,621 shares of company stock valued at $10,595. Company insiders own 32.76% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TNYA. FMR LLC increased its stake in Tenaya Therapeutics by 1.9% during the 3rd quarter. FMR LLC now owns 1,345,938 shares of the company’s stock worth $2,598,000 after buying an additional 25,503 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Tenaya Therapeutics during the third quarter worth approximately $134,000. Jacobs Levy Equity Management Inc. lifted its holdings in Tenaya Therapeutics by 204.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after purchasing an additional 226,466 shares in the last quarter. State Street Corp grew its holdings in shares of Tenaya Therapeutics by 0.9% during the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after buying an additional 9,506 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Tenaya Therapeutics by 35.6% in the third quarter. Wellington Management Group LLP now owns 294,133 shares of the company’s stock worth $568,000 after buying an additional 77,235 shares in the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.